Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — Henlius — H1 2024 Earnings Presentation
42 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, August 2024
Slide 1: Henlius (2696.HK) 2024 Interim Results Investor Presentation
Henlius (2696.HK) 2024 Interim Results Investor Presentation August 2024 © 2024 Henlius.
Slide 2: 2024 1H Business Highlights & Company Strategy
2024 1H Business Highlights & 01 Company Strategy © 2024 Henlius.
Slide 3: Revenue Tops 2.7B RMB with Net Profit of 386M RMB
Revenue Tops 2.7B RMB with Net Profit of 386M RMB Commercial Operating Revenue BD Pipeline Capacity Cash Flow 2.7B RMB 2 50+ 48KL 251m RMB Commercialization BD R&D Manufacturing Financial • Achieved sustainable and • In-licensed exclusive rights of • First subject dosed for Phase 1 • Henlius won the
Slide 4: Our Mission and Vision
Biosimilars Maximize the commercialization value in China and international markets Our Mission and Vision Innovative Drugs Explore new mechanisms, new technology platforms and expand the therapeutic area coverage Affordable Innovation Reliable Quality Globalization Develop towards a biopharma with
Slide 5: Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence
The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence • 2024 1H sales revenue of biosimilars reached 1.80 billion RMB, 12.8% YoY growth • The biosimilar pipeline covered globally popular targets such as HER2, RANKL, CTLA-4, CD38 and conducted MR
Slide 6: Serplulimab Entered into a New High-growth Stage of Commercialization
Serplulimab Entered into a New High-growth Stage of Commercialization with Differentiated Advantage Clinical Differentiated 678M RMB Advantages Indications • 20241H sales revenue reached 678M RMB Serplulimab recommended by 9 Diagnosis and ES-SCLC (marketed): Treatment Guidelines of CSCO in 2023 ASTR
Slide 7: R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs
R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs Product Type & Introduction Pipeline Distribution by Stage 28 ✓ Henlius pipeline contains 51 molecules and 14 R&D platforms ✓ Pipeline focuses around oncology while starting to explore new TAs including Autoimmune / Ophthalmology / Me
Slide 8: Globalization Has Entered into Substantial Development Stage
Globalization Has Entered into Substantial Development Stage (Marketed) HLX10-serplulimab (Marketed) HLX02-trastuzumab biosimilar, HLX01-rituximab biosimilar • Serplulimab has been approved in Indonesia, • HANQUYOU (HLX02) has marketed in 40+ countries and regions, including US, Thailand, and Cambod
Slide 9: Commercialization
02 Commercialization © 2024 Henlius.
Slide 10: HANQUYOU (Trastuzumab): Sales Growth 15.4% YoY
HANQUYOU (Trastuzumab): Sales Growth 15.4% YoY International quality Strong growth momentum • First approved trastuzumab biosimilar in China • First “Chinese nationality” mAb biosimilar approved In Billion RMB 1.47B RMB* • in Europe Approved in US and Canada, and becomes the “Chinese nationality” bi
Slide 11: Excellent Performance of HANQUYOU
Excellent Performance of HANQUYOU Strengthen product Higher sales per capita The only trastuzumab Bold expansion into broad differentiation for than domestic peers with two specifications market competitive advantages Sales Per Capita1 • 2 specifications were • Competition has become • Trastuzumab h
Slide 12: HANSIZHUANG (Serplulimab): First Approved PD-1 mAb for 1L SCLC
HANSIZHUANG (Serplulimab): First Approved PD-1 mAb for 1L SCLC Widespread recognition Differentiated strategies to seize the market In Billion RMB • Recommended in 2024 CSCO treatment guidelines for 678M RMB • SCLC, NSCLC, EC etc. First patient dosed for MRCT phase 3 study on first-line +22% Revenue
Slide 13: HANSIZHUANG Commercialization Highlights
HANSIZHUANG Commercialization Highlights Differentiation strategy to tackle First-class Commercialization Efficiency challenges and win opportunities Differentiation Strategy Outstanding Focus on SCLC Achievements (15-20% of total lung cancer patients) • Sales outperformed most of the competing • Ac
Slide 14: HANBEITAI (Bevacizumab): Commercialization Acceleration
HANBEITAI (Bevacizumab): Commercialization Acceleration Acceleration on Exploration for new medication market access and methods penetration 87M RMB • Covered by NRDL in 31 provinces, and • The only bevacizumab biosimilars with phase 3 completed tendering and procurement platform clinical data on me
Slide 15: HANLIKANG (Rituximab): Strengthen the Market Leader Position
HANLIKANG (Rituximab): Strengthen the Market Leader Position Acceleration on market access and penetration Commercialization Progress • Approved in February 2019 as the first • Jiangsu Fosun, a subsidiary of Fosun approved biosimilar in China, the first Pharma, is responsible for HANLIKANG’s 238M RM
Slide 16: HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area
HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area Improve patients’ availability and Work with partners to penetrate the accessibility market 14M RMB • Henlius’ first autoimmune disease product • Covered by NRDL and completed tendering and • Jiangsu Wanbang is responsible for China local sales
Slide 17: Business Development
03 Business Development © 2024 Henlius.
Slide 18: 2024 H1 Major Business Development In-licensing Products
2024 H1 Major Business Development In-licensing Products Sermonix Pharmaceuticals Convalife (Shanghai) Co., Ltd. Contract signing date: 2024/06/03 Contract signing date: 2024/08/19 Territory Expansion In-licensing Lasofoxifene Neratinib (HANNAIJIA) Exclusive rights in Asia & Co- Exclusive commercial
Slide 19: In-licensing Focus: Expand Portfolio into Breast Cancer Sub-types
In-licensing Focus: Leverage BD to Expand Portfolio into Different Sub-types of Breast Cancer HR+/ Lasofoxifene (small molecule SERM*): Type Breast cancer HER2+ • Lasofoxifene has tissue selectivity to the biological HER2- activities of estrogen receptor (ER); ER shows products inhibitory activity i
Slide 20: Out-licensing Focus: International Quality Biosimilars Scale up
Out-licensing Focus: Henlius’ International Quality Biosimilars Scale up across the Globe Market Size of Originators and Marketed Biosimilars Biosimilars with existing out-licensing partners Biosimilars to be out-licensed ex-China Global sales in 2023 (M USD) Global sales in 2023 (M USD) HLX17- HLX0
Slide 21: Research & Development
04 Research & Development © 2024 Henlius.
Slide 22: Product Portfolio and Pipeline
Product Portfolio and Pipeline IND Phase 1 Phase 2 Phase 3 NDA In-Market (5) HLX51 HLX6018 HLX10 (4) (serplulimab) + HLX07 HLX10 (4) (serplulimab) + Chemo HLX10 (4) (serplulimab) + Chemo HANSIZHUANG (serplulimab) (4) OX40 GARP/TGF-β1 PD-1+EGFR PD-1 PD-1 PD-1 Solid tumours, lymphomas IPF HNSCC, NPC,
Slide 23: Clinical Pipeline Milestones: 2024 1H Review
Clinical Pipeline Milestones: 2024 1H Review 2023 HLX10 HLX14 ES-SCLC2 PMOP1, etc. 1L (the Philippines) (EU & US) NDA/BLA/MAA Submission HLX10+HLX04 HLX22+HLX02 HLX14* mCRC3 GC4 PMOP5 1L (PoC) 1L (PoC) (Pivotal) Key Clinical Data Readouts Innovative mAb mAb biosimilar 1. Postmenopausal osteoporosis
Slide 24: Clinical Pipeline Milestones: Expected in 2024 2H & 2025 1H
Clinical Pipeline Milestones: Expected in 2024 2H& 2025 1H 2024H2 2025H1 HLX10 HLX10 ES-SCLC1 HLX10 MSI-H solid tumors HLX10 HLX10 1L (Hong Kong SAR, sqNSCLC2 Late-line (Hong ESCC3 ES-SCLC1 Macao SAR, Vietnam, 1L (India, Macao Kong SAR, Macao 1L (Macao SAR, 1L (US) UK, India, Swit, MENA) SAR) SAR, I
Slide 25: Clinical Data of HLX10-015-CRC301
Clinical Data of HLX10-015-CRC301 Data cut-off date: 2023/12/15; median follow-up duration: 24.4 months • The latest clinical data of the phase 2/3 results (HLX10-015-CRC301) of HANSIZHUANG (HLX10, serplulimab)+HANBEITAI (HLX04, bevacizumab)+XELOX for 1L mCRC (metastatic colorectal cancer) treatment
Slide 26: Serplulimab: Targeting Differentiated Indications
Serplulimab: Targeting Differentiated Indications According to the baseline data analysis of 649 subjects in the Checkmate, 60% advanced GC patients had CPS ≥ 5. The trial design had focused on PD-L1-positive patients (CPS ≥ 5) from Gastric Cancer the very beginning. Serplulimab aims to be the world
Slide 27: HLX22: Potential to Change the SOC of 1L GC
HLX22: Potential to Change the SOC of 1L GC HLX22 (HER2) • HLX22 targets at different epitopes within domain IV of Her2, the results demonstrated that HLX22 and trastuzumab (HLX02) simultaneously bind to HER2 subdomain IV, which subsequently facilitate the endocytosis of both HER2/HER2 homodimers an
Slide 28: Clinical Data of HLX22-GC-201
Clinical Data of HLX22-GC-201 Data cut-off date: 2024/03/25 ; median follow-up duration: 22.1 months • The clinical data of Phase 2 study (HLX22-GC-201) of HLX22 (an innovative anti-HER2 mAb)+HANQUYOU (HLX02, trastuzumab)+XELOX for the 1L HER2-positive gastric/gastroesophageal junction (G/GEJ) cance
Slide 29: Pre-clinical Assets
4.1 Pre-clinical Assets © 2024 Henlius.
Slide 30: HLX43 (PD-L1 ADC) Preclinical Efficacy Data, Entered Phase 1
HLX43 (PD-L1 ADC) Presented Excellent Preclinical Efficacy Data and Entered into Clinical Phase 1 Preclinical Results HLX43 Shows No Immunotoxicity HLX43 Exhibits Excellent Towards PD-L1+ Human APCs Bystander Effect • HLX43 shows no immunotoxicity towards PD-L1+ human APCs • HLX43 exhibits excellent
Slide 31: HLX42 (EGFR ADC) Preclinical Data, Fast Track Designation
HLX42 (EGFR ADC) Presented Excellent Preclinical Efficacy Data, Granted Fast Track Designation by FDA, and Entered into Clinical Phase 1 Preclinical Results HLX42 Exhibits Excellent HLX42 Exhibits Excellent Anti- • HLX43 exhibits excellent bystander effect Bystander Effect tumor Efficacy In vivo • I
Slide 32: Three Major Preclinical Platforms Drive Full-Speed Development
Three Major Preclinical Platforms Drive Full-Speed Development of Representative Molecules Protein drug discovery and engineering HanjugatorTM: AI4T (AI for Therapeutics) to drive platform to enable innovative therapeutic Modular ADC toolbox and development innovative drug discovery for oncology, R&
Slide 33: HLX6018: First-in-class Anti-Pulmonary/Kidney Fibrosis Candidate
HLX6018: First-in-class anti-Pulmonary/Kidney Fibrosis Candidate, Phase 1 ongoing Project information Key data ⚫ Indication ⚫ Pharmacology 2. HLX6018 inhibits the release of TGFβ1 Pulmonary fibrosis: Currently approved 1. HLX6018 specifically binds to GARP/TGFβ1(no effects on TGFβ2,3) and inhibits i
Slide 34: Manufacturing
05 Manufacturing © 2024 Henlius.
Slide 35: International Leading Capabilities on Manufacturing and Quality Management
International Leading Capabilities on Manufacturing and Quality Management Xuhui Site Songjiang Songjiang L L 1st Plant 2nd Plant 0 0 00 00 4, 4, 2 2 • Manufacturing capacity optimization: • Global GMP standards: Passed Pre- • Plant construction for Phase 1 & 2 trials: Commercial GMP production batc
Slide 36: Operation Excellence and Continuous Innovation
Operation Excellence and Continuous Innovation Technical Innovation Lean Operations Multiple Regression Analysis Model Lean 30+ on-going lean operations projects for Prediction with ~10M RMB* expected annualized The objects for multiple regression Operations returns analysis have been locked, and da
Slide 37: 2024H1 Financial Review
06 2024H1 Financial Review © 2024 Henlius.
Slide 38: 2024 Half Year Revenue of RMB 2.75 Billion with 9.8% YoY
2024 Half Year Revenue of RMB 2.75 Billion with 9.8% YoY Revenue (in Billion RMB) Product Sales (in Billion RMB) 2024 Revenue Breakdown (in Million RMB) 2024 2023 2024 revenue for illustration %2024 share % 15.2% 9.8% 93.9% 82.2% 2.5 2.7 2.5 2.2 53.7% 1,474 1,278 1.3 1.2 24.7% 8.3% 678 9.7% 556 3.2%
Slide 39: Achieved Profitability in 2024H1 with RMB ~251M Operating CF
Achieved Profitability in 2024H1 with RMB ~251M Operating CF Net profit (net loss): turned into profitability (in Million RMB) R&D related investment (in Million RMB) Net profit (net loss) margin Net profit (net loss) Cost of Services Provided* Capitalized Expensed 14.1% 9.6% 1151 903 1013 386 302 2
Slide 40: Financial Highlights
Financial Highlights Financial Data (selected) 24H1 23H1 YoY Growth Unit In Million RMB % of revenue In Million RMB % of revenue % Revenue 2,746.1 100.0% 2,500.5 100.0% 9.8% Product sales 2,479.4 90.3% 2,152.9 86.1% 15.2% BD and other revenue 266.7 9.7% 347.6 13.9% (23.3%) Cost of sales (755.4) (27.
Slide 41: Disclaimer
Disclaimer • Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements), including but not limited to the statements about the timelines
Slide 42: © 2024 Henlius.
@ Henlius Reliable Quality Affordable Innovation